Recently, ketogenic diet has been recognized a useful treatment strategy for glioblastoma in vitro. Therefore, the purpose of the study is to evaluate the safety and efficacy of ketogenic adjuvant to salvage chemotherapy for recurrent glioblastoma.
Diet change by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and inhibit tumor growth. In a pilot of recurrent glioblastoma, ketogenic diet adjuvant salvage chemotherapy was given as interventional group and standard diet adjuvant salvage chemotherapy was given as control group. The study examines whether a ketogenic diet adjunctive to salvage chemotherapy can be applied to the patients and may inhibit tumor growth and influence the quality of life of the patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
RECRUITINGNumber of Participants with Treatment-emergent Adverse Effects
Number of participants with treatment-emergent adverse effects while on ketogenic diet.
Time frame: one year
The Chemosensitivity of Tumor
MRI(Magnetic Resonance Imaging) will be used to measure changes in brain tumor size (cm\^2).
Time frame: one year
Overall Survival
Participants were followed until reported death
Time frame: one year
Ketosis
Urine and blood ketosis (mmol/L) were measured
Time frame: one year
Quality of Life
quality of life measured by the Karnofsky Performance Scale
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.